ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,995.54
      0.38%
      US Tech 100
      20,560.80
      0.09%
      Dow Jones
      43,988.99
      0.59%
      Brent Oil
      73.885
      -2.09%
      Bitcoin
      76,523.24
      0.82%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      Lexicon Pharmaceuticals Inc

      Lexicon Pharmaceuticals Inc (LXRX)

      NASDAQ
      1.27
      -0.03
      (-2.31%)
      At close: November 08 4:00PM
      Delayed by 15 minutes
      1.27
      0.00
      ( 0.00% )
      After Hours: 4:56PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      LXRX News

      Official News Only

      Form 8-K - Current report
      Edgar (US Regulatory)
      October 16 2024
      LXRX (-2.31%)

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      October 07 2024
      LXRX (-2.31%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      September 16 2024
      LXRX (-2.31%)

      LXRX Discussion

      View Posts
      BooDog BooDog 1 week ago
      FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 20, 2024.

      Chances are looking pretty slim though.
      https://www.globenewswire.com/news-release/2024/10/31/2973110/0/en/Lexicon-Announces-Outcome-of-FDA-Advisory-Committee-for-Zynquista-sotagliflozin-as-an-Adjunct-to-Insulin-Therapy-for-Glycemic-Control-in-Adults-with-Type-1-Diabetes-and-Chronic-Kid.html
      👍️0
      BooDog BooDog 1 week ago
      Nothing wrong with locking in some green. Ilike how the chart is setting up.

      GL
      👍️0
      Judah137 Judah137 1 week ago
      Glad I sold my 20,000 shares yesterday instead of waiting until today 😅🙄😢. Maybe back in tomorrow...
      👍️0
      BooDog BooDog 3 weeks ago
      Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
      Viatris OUS Logo (PRNewsfoto/Viatris Inc.)
      News provided by
      Viatris Inc.
      Oct 16, 2024, 16:34 ET

      Share this article

      Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases
      Leverages Viatris' Unique Global Infrastructure and Expertise
      Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications
      PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe.

      https://www.prnewswire.com/news-releases/viatris-announces-exclusive-licensing-agreement-with-lexicon-pharmaceuticals-for-sotagliflozin-in-all-markets-outside-of-the-us-and-europe-302278473.html
      👍️0
      BooDog BooDog 1 month ago
      LXRX 10/18/2024 2.50 C Thinking the call action will be very much in play. I'm thinking shorts will need to cover soon.

      Just my opinion.
      👍️ 1
      Judah137 Judah137 1 month ago
      Shorts keep increasing positions! 27.45m short as of today!! Betting against the institutions who took massive ownership in Q2??? Betting against the AdCom????
      👍️0
      BooDog BooDog 2 months ago
      News: New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
      September 10, 2024 08:00 ET
      | Source: Lexicon Pharmaceuticals, Inc.
      Share






      Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin

      TIR measures approach target set by American Diabetes Association

      Data to be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online

      THE WOODLANDS, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial demonstrated that once-daily dosing of sotagliflozin 400 mg improved time-in-range (TIR) and several continuous glucose monitoring (CGM) parameters, including glucose variability, in insulin-treated type 2 diabetes (T2D) patients. Researchers also observed positive trends with the once-daily dose of 200 mg. Study findings will be presented September 12th at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online.

      The objective of the SOTA-INS CGM study was to evaluate the effect of sotagliflozin on TIR as assessed by CGM in people with T2D. The primary sub-study endpoint was mean change in percentage of time spent within TIR (glucose 70-180 mg/dL [3.9-10.0 mmol/L]) over 24 hours for sotagliflozin 400 mg versus placebo.

      The American Diabetes Association recommends a TIR target of at least 70% (17 hours) in people with type 1 diabetes (T1D) or T2D. In this study, sotagliflozin 200 mg and 400 mg once daily TIR (15.3 and 15.9 hours, respectively) approached the ADA target, with modest reductions in time-above-range (TAR) and mild increases in time-below-range (TBR).

      Sotagliflozin has previously demonstrated glycemic efficacy and improvements in TIR as an adjunct to insulin therapy in people with T1D who participated in the inTandem clinical trial program.


      https://www.globenewswire.com/news-release/2024/09/10/2943581/0/en/New-Secondary-Analysis-of-Phase-3-Data-Demonstrates-Sotagliflozin-Improves-Time-In-Range-TIR-and-Several-Parameters-of-Glucose-Control-and-Variability-in-Basal-Insulin-Treated-Type.html
      👍️0
      Monksdream Monksdream 2 months ago
      LXRX under $2
      👍️0
      BooDog BooDog 3 months ago
      Back under $2 again, printing 1.70's. Setting up for another swing.
      👍️0
      Monksdream Monksdream 4 months ago
      LXRX under $2
      👍️0
      BooDog BooDog 4 months ago
      Just may be an early Christmas. https://www.globenewswire.com/news-release/2024/07/16/2913701/0/en/Lexicon-Pharmaceuticals-Receives-December-20-2024-PDUFA-Goal-Date-for-Sotagliflozin-Type-1-Diabetes-NDA-Resubmission.html
      👍️0
      Monksdream Monksdream 4 months ago
      LXRX under $2
      👍️ 1
      jdheart101 jdheart101 6 months ago
      Garbage
      👍️0
      dcaf7 dcaf7 6 months ago
      Interesting sales estimates for Sota.
      Apr 30, 2024
      Leerink initiated coverage of Lexicon with an Outperform rating and $5 price target. The firm believes Lexicon’s first-in-class dual SGLT1/2 inhibitor sotagliflozin could address unmet need across multiple indications with large market opportunities, including heart failure, hypertrophic cardiomyopathy and Type 1 diabetes with chronic kidney disease, which could collectively drive blockbuster sales. Inpefa’s U.S. launch in HF should benefit from several meaningful tailwinds, Leerink says. It forecasts peak U.S. sales of $1B for Inpefa in HF and peak U.S. sales of $325M for sotagliflozin in HCM in FY32. The firm also points out that Lexicon plans to resubmit Zynquista’s NDA filing by mid-2024, with an anticipated 6-month review. Leerink forecasts peak U.S. sales of $225M for Zynquista in T1D with CKD in FY32.
      👍️0
      BooDog BooDog 7 months ago
      Almost added back in but want to see confirmation for bottom. Double bottoms can be tricky. But even so, long term I like this.
      👍️0
      BooDog BooDog 7 months ago
      Zacks analysis.
      https://www.zacks.com/stock/news/2256264/all-you-need-to-know-about-lexicon-lxrx-rating-upgrade-to-buy

      Upgrading to buy while I'm watching for the gap to fill which may put this around 1.40's. We'll see. I think analysts are always late to the party but this report is actually pretty timely.
      👍️0
      BooDog BooDog 7 months ago
      Quite the gap there if that's what you're looking at.
      👍️0
      glenn1919 glenn1919 7 months ago
      LXRX.......................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      dcaf7 dcaf7 8 months ago
      Lexicon will resubmit an NDA for sotagliflozin for patients with type 1 diabetes and chronic kidney disease. Good news. FDA rejected an NDA for type 1 diabetes in 2019. Now they changed their mind but only for patients with T1D+CKD. According to today's company presentation, slide 10, this population makes 21% of adults with T1D, or ~357,000 patients. Not a big addition to current indication. However, it will be the first gliflozin approved for T1D. No competition.
      👍️ 1
      Awl416 Awl416 8 months ago
      Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
      👍️0
      BooDog BooDog 8 months ago
      Earnings expected next Thursday, a miss or a hit? Revenue a hit imo.

      Form 4 filed
      👍️0
      jdheart101 jdheart101 9 months ago
      200 July 2.5 calls @.88 . Be back soon !!!
      👍️0
      TIMGZ TIMGZ 9 months ago
      INBS**** AS ALWAYS SUPER FAST COMPUTERS***WHALES***HEDGES FUNDS*** TRADERS MIGHT SURGE THE VOLUME AT A VERY HIGH FREQUENCY****


      WITHIN MINUTES*****UPTREND

      SEEMS SETTING UP NICELY FOR THAT
      👍️0
      BooDog BooDog 9 months ago
      Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.

      👍️0
      glenn1919 glenn1919 9 months ago
      LXRX..........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      jdheart101 jdheart101 9 months ago
      Another 4000. @1.76
      👍️0
      Legend431 Legend431 10 months ago
      Oops
      👍️0
      jdheart101 jdheart101 10 months ago
      I’m in today 9500 @1.49 1/23/24
      👍️0
      BooDog BooDog 11 months ago
      Ready to see this rock and roll. Get the Christmas rally going!

      https://www.inpefahcp.com/


      Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
      Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
      Dec 6, 10:18?AM EST - Disclaimer
      Headquarters: The Woodlands, TX
      CEO: Lonnel Coats (Jul 7, 2014–)
      Revenue: 324.1 million USD (2019)
      Number of employees: 225 (2011)
      Founded: 1995, The Woodlands, TX
      Founder: Arthur T Sands
      Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
      Product
      https://www.lexpharma.com/

      https://www.lexpharma.com/media-center/news
      👍️0
      BooDog BooDog 12 months ago
      Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

      https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM
      👍️0
      Monksdream Monksdream 12 months ago
      LXRX new 52 week low
      👍️0
      BooDog BooDog 1 year ago
      $LXRX. Looking good. See this in a week or 2.

      JMHO.
      👍️0
      glenn1919 glenn1919 1 year ago
      LXRX................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      TRADER99 TRADER99 1 year ago
      Looks like we saw a bottom here with this spike in volume
      👍️0
      Monksdream Monksdream 1 year ago
      LXRX new 52 week low
      👍️0
      BooDog BooDog 1 year ago
      Guess I wasn't watching the board here Monk. Have been watching the chart though and have been accumulating around 1.10' last week and added today.

      Cheers
      👍️0
      Monksdream Monksdream 1 year ago
      LXRX new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      LXRX new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      LXRX new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      LXRX new 52 week low
      👍️0
      BooDog BooDog 1 year ago
      LXRX 1.70's. Watching.
      👍️0
      BooDog BooDog 1 year ago
      $LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
      Conference call this morning...

      Conference Call and Webcast Information

      Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
      👍️0
      BooDog BooDog 1 year ago
      👍️0
      BooDog BooDog 1 year ago
      Quite the boost for institutionals.
      https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm
      👍️0
      BooDog BooDog 1 year ago
      Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
      Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.
      👍️0
      TIMGZ TIMGZ 1 year ago
      LXRX MIGHT NOT BE LOOKING BACK AGAN, FDA APPROVED DRUG AND ALL BIG PHARMA EYEING. MY OPINION *******
      ONE PAID $260M FOR BACKING OUT, NOW LOOK AT LXRX
      👍️ 1
      BooDog BooDog 1 year ago
      2.75 support. See how it holds, or not. Interesting sell off.
      👍️0
      glenn1919 glenn1919 1 year ago
      LXRX.........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      BooDog BooDog 1 year ago
      Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.
      👍️0
      glenn1919 glenn1919 1 year ago
      LXRX...........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0

      Your Recent History

      NASDAQ
      LXRX
      Lexicon Pharmaceuticals
      ASX
      ADRN
      Adherium
      USOTC
      GKSDF
      Grupo Kuo SAB de CV (CE)
      COIN
      NOIAUSD
      Syntropy [NOIA Token]
      BIT
      Q00319
      Leonteq Securities
      Delayed Upgrade Clock